glp-1 for depression Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of | Pharmacological Reports New Study: GLP-1s REDUCED Depression

Description

This is the number of calories your body burns at rest, just to keep you alive

American Journal of Clinical Nutrition, 103(3), 738746

Muscle pain and body aches sometimes appear, especially at higher doses

Abstract The unprecedented clinical success of glucagon-like peptide-1 (GLP-1) receptor agonists has transformed the therapeutic landscape for obesity, diabetes, and cardiometabolic disease, while simultaneously reshaping long-standing perceptions of peptide-based therapeutics as biologically compelling but pharmacologically impractical

Contemporary OB-GYN: FDA approves-5-year-use-for-etonogestrel-implant-68-mg-contraceptive Safety Labeling Update for Nexplanon Patient Experiences with Nexplanon Summary of MedWatch Voluntary Reports for Nexplanon (240 reports of device complications for 1,577 reports submitted voluntarily, mainly by consumers) Rare Disease: FDA Approves First Treatment for Children With Menkes Disease The FDA approved the first-ever treatment for Menkes disease: Zydus Life Sciences Zycubo (copper histidinate) daily subcutaneous injection for pediatric patients